Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage. 2006

Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
Department of Medicine, University of California San Francisco, San Francisco, CA 94143-0124, USA.

OBJECTIVE Whether cardiac dysfunction contributes to morbidity and mortality after subarachnoid hemorrhage (SAH) remains controversial. The objective of this study was to test the hypothesis that cardiovascular abnormalities are independently related to in-patient mortality after SAH. METHODS This was a prospective cohort study of patients with aneurysmal SAH. Heart rate and blood pressure were measured, a blood sample was obtained, and echocardiography was performed on three study days, starting as soon after admission as possible. The cardiovascular predictor variables were heart rate, systolic blood pressure (SBP), cardiac troponin I (cTi) level, B-type natriuretic peptide (BNP) level, and left ventricular ejection fraction. The primary outcome measure was in-patient mortality. The association between each predictor variable and mortality was quantified by multivariate logistic regression, including relevant covariates and reporting odds ratios (OR) and 95% confidence intervals (CI). RESULTS The study included 300 patients. An initial BNP level greater than 600 pg/mL was markedly associated with death (OR 37.7, p < 0.001). On the third study day (9.1 +/- 4.1 days after SAH symptom onset), a cTi level greater than 0.3 mg/L (OR 7.6, p = 0.002), a heart rate of 100 bpm or greater (OR 4.9, p = 0.009), and a SBP less than 130 mmHg (OR 6.7, p = 0.007) were significantly associated with death. CONCLUSIONS Cardiovascular abnormalities are independent predictors of in-patient mortality after SAH. Though these effects may be explained by a reduction in cerebral perfusion pressure or other mechanisms, further research is required to determine whether or not they are causal in nature.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010656 Phenylephrine An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol,Metaoxedrin,Metasympatol,Mezaton,Neo-Synephrine,Neosynephrine,Phenylephrine Hydrochloride,Phenylephrine Tannate,Neo Synephrine,Tannate, Phenylephrine
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D002319 Cardiovascular System The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body. Circulatory System,Cardiovascular Systems,Circulatory Systems
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
December 2012, Neurocritical care,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
September 1995, Lakartidningen,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
February 2004, Stroke,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
January 2002, Stroke,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
March 2012, Neurology,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
December 2013, Neurocritical care,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
July 2017, Neurology,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
January 2011, Acta neurochirurgica. Supplement,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
July 2015, Clinical chemistry and laboratory medicine,
Sirisha Yarlagadda, and Pam Rajendran, and Jacob C Miss, and Nader M Banki, and Alexander Kopelnik, and Alan H B Wu, and Nerissa Ko, and Adrian W Gelb, and Michael T Lawton, and Wade S Smith, and William L Young, and Jonathan G Zaroff
December 2020, Acta neurochirurgica,
Copied contents to your clipboard!